The limited efficacy of IL-1 blockers in RA therefore appears not to be explained solely by pharmacokinetic or pathway coverage, since the efficacy provided by AMG 108 was similar to that in other IL-1 inhibitor studies [27] despite constant inhibition of the IL-1 pathway for a 6-month period with AMG 108. Here, IL1B is linked to rheumatoid arthritis.